BMPR2 mutation and clinical response to imatinib in a case of heritable pulmonary arterial hypertension
10 January 2024
Shine Kumar, Lalitha Biswas, Anju Choorakottayil Pushkaran, Raman Krishna Kumar
https://doi.org/10.1002/pul2.12335
Abstract
Bone morphogenetic protein receptor 2 (BMPR2) mutation is the most common gene mutation implicated in the pathogenesis of pulmonary arterial hypertension (PAH). We describe, for the first time, an excellent clinical response to tyrosine kinase inhibitor imatinib in a patient with heritable PAH from BMPR2 mutation.
accuracy.
Additional comments are available to members. Login or register to become a member today
RegisterorLogin to view